Abstract
Methylation status of a select panel of genes can predict failure of bacillus Calmette–Guerin (BCG) immunotherapy, according to research carried out by Marta Sanchez-Carbayo and colleagues at the Spanish National Cancer Research Centre in Madrid. Intravesical BCG is the treatment of choice for patients with non-muscle-invasive bladder cancer who are considered to be at high risk of recurrence and progression to muscle-invasive disease. However, about a third of recipients do not respond to BCG, and the ability to identify which patients might require more-aggressive management is a major goal of bladder cancer research today.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
